The Latest Cardiac and Vascular News
Primary safety analysis of Stellarex drug-coated balloon (DCB) three-year data, comprising the largest published, pooled set of randomized controlled trial (RCT) data for a single paclitaxel-based device, shows no difference in mortality between patients treated with the Philips Stellarex DCB and those treated with percutaneous angioplasty, the current standard of […]
SAN CARLOS, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) — BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the U.S. commercial availability of its AVANCE™ Bi-Directional Steerable Introducer Sheath for introducing various cardiovascular catheters into the heart, including via the left side of the heart through […]
– New data presented at TCT 2019 on Abbott’s TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints – Abbott’s TriClip tricuspid valve repair system design is based on the company’s market-leading MitraClip™ technology SAN FRANCISCO, Sept. 28, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new […]
VANCOUVER, Sept. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ (“Tiara”) transcatheter mitral valve replacement […]
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. […]
MAPLE GROVE, Minn., Sept. 30, 2019 /PRNewswire/ — 4C Medical Technologies, Inc., the creator of a new generation of therapies for structural heart disease, announced today that its medical device therapy for mitral regurgitation (MR), AltaValve™, was featured at Transcatheter Cardiovascular Therapeutics (TCT) 2019, on Sept 25-29 in San Francisco, CA. The AltaValve is a Transcatheter […]
BETonMACE did not meet the primary endpoint Apabetalone development to continue to be advanced by the Company based on BETonMACE results Primary results to be presented during a late-breaking science session at AHA 2019 Apabetalone demonstrated tolerability and safety Resverlogix to host investor webcast and conference call on Monday, September […]
Nearly 80% of randomized patients have completed the studies Data clean-up for TRILOGY 1 is 90% completed Plan to present full data set including results for key secondary and exploratory endpoints of interest such as non-HDL-C, LDL-C, VLDL, HDL-C and HbA1c at key scientific meetings in 2020 […]
During a heart attack, cardiologists say “time is muscle.” The time between when you arrive at the hospital and when your blockage is opened matters. The American Heart Association recommends a “door-to-balloon time” (D2B) of no more than 90 minutes. University Hospitals Portage Medical Center in Ravenna, Ohio blew that […]
New Study Shows Momentum in Establishing a Less Invasive Approach to Treat Patients with Severe Mitral Valve Disease DUBLIN, Sept. 27, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its Intrepid™ transcatheter mitral […]
